[{"address1": "201 Haskins Way", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 695 0677", "website": "https://www.lyell.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 300, "companyOfficers": [{"maxAge": 1, "name": "Dr. Richard D. Klausner M.D.", "age": 72, "title": "Founder & Executive Chairman", "yearBorn": 1952, "fiscalYear": 2024, "totalPay": 82734, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lynn  Seely M.D., Ph.D.", "age": 65, "title": "President, CEO & Director", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 1021376, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen J. Hill", "age": 53, "title": "Chief Operating Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 750442, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Stanley R. Riddell M.D.", "title": "Founder & Scientific Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Crystal L. Mackall M.D.", "age": 63, "title": "Founder & Scientific Advisor", "yearBorn": 1961, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles W. Newton", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 744737, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Nellie  Dillery", "title": "Director of Accounting", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gary K. Lee Ph.D.", "age": 47, "title": "Chief Scientific Officer", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 889676, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ellen  Rose", "title": "Senior Vice President of Communications & Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark A. Meltz J.D.", "age": 50, "title": "General Counsel & Corporate Secretary", "yearBorn": 1974, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 17.0, "open": 17.01, "dayLow": 16.475, "dayHigh": 17.2899, "regularMarketPreviousClose": 17.0, "regularMarketOpen": 17.01, "regularMarketDayLow": 16.475, "regularMarketDayHigh": 17.2899, "payoutRatio": 0.0, "beta": -0.079, "forwardPE": -19.642859, "volume": 24481, "regularMarketVolume": 24481, "averageVolume": 53990, "averageVolume10days": 33330, "averageDailyVolume10Day": 33330, "bid": 16.13, "ask": 17.04, "bidSize": 1, "askSize": 1, "marketCap": 316984832, "fiftyTwoWeekLow": 7.65, "fiftyTwoWeekHigh": 30.0, "allTimeHigh": 396.8, "allTimeLow": 7.65, "priceToSalesTrailing12Months": 5283.0806, "fiftyDayAverage": 13.4071, "twoHundredDayAverage": 11.3391, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 95301832, "profitMargins": 0.0, "floatShares": 12047345, "sharesOutstanding": 19211202, "sharesShort": 233067, "sharesShortPriorMonth": 145675, "sharesShortPreviousMonthDate": 1756425600, "dateShortInterest": 1759190400, "sharesPercentSharesOut": 0.0121, "heldPercentInsiders": 0.20562, "heldPercentInstitutions": 0.50004, "shortRatio": 3.82, "shortPercentOfFloat": 0.0149, "impliedSharesOutstanding": 19793360, "bookValue": 20.155, "priceToBook": 0.8186554, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -331396992, "trailingEps": -24.26, "forwardEps": -0.84, "lastSplitFactor": "1:20", "lastSplitDate": 1748822400, "enterpriseToRevenue": 1588.364, "enterpriseToEbitda": -0.489, "52WeekChange": -0.26339287, "SandP52WeekChange": 0.13837254, "quoteType": "EQUITY", "currentPrice": 16.5, "targetHighPrice": 20.0, "targetLowPrice": 10.0, "targetMeanPrice": 14.0, "targetMedianPrice": 12.0, "recommendationKey": "none", "numberOfAnalystOpinions": 3, "totalCash": 276790016, "totalCashPerShare": 14.408, "ebitda": -194868000, "totalDebt": 55107000, "quickRatio": 7.5, "currentRatio": 7.647, "totalRevenue": 60000, "debtToEquity": 18.435, "revenuePerShare": 0.004, "returnOnAssets": -0.25388, "returnOnEquity": -0.76585996, "grossProfits": 60000, "freeCashflow": -81777752, "operatingCashflow": -171480000, "revenueGrowth": -0.385, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -5412.125, "financialCurrency": "USD", "symbol": "LYEL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Lyell Immunopharma, Inc.", "longName": "Lyell Immunopharma, Inc.", "corporateActions": [], "postMarketTime": 1760731804, "regularMarketTime": 1760731201, "marketState": "CLOSED", "regularMarketChangePercent": -2.94118, "regularMarketPrice": 16.5, "hasPrePostMarketData": true, "epsTrailingTwelveMonths": -24.26, "epsForward": -0.84, "fiftyDayAverageChange": 3.0929003, "fiftyDayAverageChangePercent": 0.23069122, "twoHundredDayAverageChange": 5.1609, "twoHundredDayAverageChangePercent": 0.45514196, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-17", "cryptoTradeable": false, "firstTradeDateMilliseconds": 1623936600000, "postMarketChangePercent": 0.0, "postMarketPrice": 16.5, "postMarketChange": 0.0, "regularMarketChange": -0.5, "regularMarketDayRange": "16.475 - 17.2899", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 53990, "fiftyTwoWeekLowChange": 8.85, "fiftyTwoWeekLowChangePercent": 1.1568627, "fiftyTwoWeekRange": "7.65 - 30.0", "fiftyTwoWeekHighChange": -13.5, "fiftyTwoWeekHighChangePercent": -0.45, "fiftyTwoWeekChangePercent": -26.339287, "earningsTimestampStart": 1763064000, "earningsTimestampEnd": 1763064000, "isEarningsDateEstimate": true, "exchange": "NMS", "messageBoardId": "finmb_590661061", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Lyell Immunopharma", "trailingPegRatio": null, "__fetch_time": "2025-10-18"}]